Rachel K. King
CIK: 0001589712
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Jun 30, 2026FULC
Fulcrum Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
32K shares- - Jun 20, 2026NVAX
NOVAVAX INC
Exercise(M)Direct18.9K shares- - Jun 18, 2026NVAX
NOVAVAX INC
Award(A)DirectStock Option (Right to Buy)
21.3K shares- - Jun 18, 2026NVAX
NOVAVAX INC
Award(A)DirectRestricted Stock Units
14.2K shares- - Jun 26, 2025FULC
Fulcrum Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
36K shares- - Jun 20, 2025NVAX
NOVAVAX INC
Award(A)DirectRestricted Stock Units
18.9K shares- - Jun 20, 2025NVAX
NOVAVAX INC
Award(A)DirectStock Option (Right to Buy)
28.3K shares at avg. $6.42- - Jun 12, 2025NVAX
NOVAVAX INC
Exercise(M)Direct10.4K shares- - Dec 13, 2024NVAX
NOVAVAX INC
Sale(S)Direct4.2K shares at avg. $9.02$37K - Nov 12, 2024FULC
Fulcrum Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
60K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 30, 2026 |  FULC Fulcrum Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 32,000 | - | - | Direct |
| Jun 20, 2026 |  NVAX NOVAVAX INC | Exercise(M) | 18,880 | - | $0 | Direct |
| Jun 18, 2026 | NVAX NOVAVAX INC | Award(A) Stock Option (Right to Buy) | 21,270 | - | - | Direct |
| Jun 18, 2026 | NVAX NOVAVAX INC | Award(A) Restricted Stock Units | 14,180 | - | - | Direct |
| Jun 26, 2025 | FULC Fulcrum Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 36,000 | - | - | Direct |
| Jun 20, 2025 | NVAX NOVAVAX INC | Award(A) Restricted Stock Units | 18,884 | - | - | Direct |
| Jun 20, 2025 | NVAX NOVAVAX INC | Award(A) Stock Option (Right to Buy) | 28,326 | $6.42 | - | Direct |
| Jun 12, 2025 | NVAX NOVAVAX INC | Exercise(M) | 10,420 | - | - | Direct |
| Dec 13, 2024 | NVAX NOVAVAX INC | Sale(S) | 4,150 | $9.02 | $37,435 | Direct |
| Nov 12, 2024 | FULC Fulcrum Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 60,000 | - | - | Direct |
1-10 of 10 transactions
About King Rachel K.
King Rachel K. (SEC CIK 0001589712) files insider reports with the SEC as Director of Fulcrum Therapeutics, Inc. (FULC) and Director of NOVAVAX INC (NVAX).
Signal8 holds 8 ownership filings by King Rachel K. (1 Form 3, 7 Form 4), filed between Nov 14, 2024 and Jul 2, 2026. Those filings report 10 transactions, from Nov 12, 2024 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on King Rachel K.'s filings is in CAMBRIDGE, MA.
Recent filings by King Rachel K.
- Jun 30, 2026: Grant or award of FULC derivative securities (Form 4, code A).
- Jun 20, 2026: Option exercise of NVAX shares (Form 4, code M).
- Jun 18, 2026: Grants or awards of NVAX derivative securities (2 lines, Form 4, code A).
- Jun 26, 2025: Grant or award of FULC derivative securities (Form 4, code A).
- Jun 20, 2025: Grants or awards of NVAX derivative securities (2 lines, Form 4, code A).
Other insiders filing for Fulcrum Therapeutics, Inc. (FULC)
- TANG KEVIN, 10% Owner
- Banks Sonja, Director
- Dorton Katina, Director
- Gould Robert J, Director
- Haviland Kate, Director
- GERAGHTY JAMES A, Director